Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHIPELAGO
NCT00296218Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of irbesartan in acute coronary syndrome (ACS) (2 arms), sponsored by Sanofi. Primary endpoint: High-sensitivity C-reactive protein at Day 60. Started Feb 2006; status: completed.
02
Drugs
irbesartan
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00296218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296218.